PALISADE BIO, INC. (PALI) - Dilution Analysis

10-Q filing | 173.6M shares outstanding

S-3 filing: This S-3 filing registers an aggregate of $300,000,000 of various securities, including common stock, preferred stock, debt securities, and warrants, which may be offered from time to time.

8-K filing: Palisade Bio, Inc. issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health for $3.0 million at a price of $1.952 per share. ($3.0M proceeds)

10-K filing | 165.9M shares outstanding

S-3 filing: The filing relates to the offer and resale of up to 8,896,944 shares of common stock by selling stockholders, consisting of shares issuable upon exercise of a warrant and placement agent warrants.

10-Q filing | 9.1M shares outstanding

S-1 filing: This S-1 filing relates to an offering of common stock and pre-funded warrants by Palisade Bio, Inc.

10-Q filing | 4.8M shares outstanding

10-K filing | 4.4M shares outstanding

8-K filing: Palisade Bio, Inc. closed a public offering on December 13, 2024, selling Class A and Class B Units, each containing common stock or prefunded warrants and common warrants, resulting in net proceeds of approximately $4.10 million, and also repriced outstanding common stock warrants to $1.40 per share.

POS AM filing: This POS AM filing relates to an underwritten public offering of Class A Units, Class B Units, and warrants to the underwriter.

S-1/A filing: The company is offering Class A Units, Class B Units, representative warrants, and common stock issuable upon exercise of pre-funded warrants, common warrants, and representative warrants.

S-1/A filing: The company is offering shares of common stock, pre-funded warrants to purchase common stock, and representative warrants to purchase common stock.

S-1/A filing: This S-1/A filing outlines an offering of 2,057,613 shares of common stock at an assumed price of $2.43 per share, along with pre-funded warrants and representative warrants, and includes an underwriter option for additional shares to cover over-allotments.

10-Q filing | 1.3M shares outstanding

S-1 filing: This S-1 filing is for an offering of common stock, pre-funded warrants, and representative warrants, with the underwriters having a 45-day option to purchase additional shares to cover over-allotments.

10-Q filing | 1.2M shares outstanding

10-Q filing | 0.9M shares outstanding

S-3 filing: This S-3 filing registers 1,575,019 shares of common stock for resale by selling stockholders, including shares and shares underlying warrants issued in a private placement on May 6, 2024.

8-K filing: Palisade Bio, Inc. entered into a securities purchase agreement for a private placement involving the sale of common stock, prefunded warrants, and warrants, expected to close around May 6, 2024, for approximately $4.0 million in gross proceeds. ($0.0M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 12,771,015 → 851,401

S-3 filing: The filing registers 3,627,623 shares of common stock issuable upon the exercise of common stock purchase warrants for resale by selling stockholders.

10-K filing | 12.8M shares outstanding

8-K filing: Palisade Bio, Inc. entered into warrant inducement agreements with certain holders of its outstanding warrants, reducing the exercise price to $0.7313 per share and issuing replacement warrants. ($2.5M proceeds)

RW filing: Palisade Bio, Inc. is requesting the SEC to consent to the withdrawal of their Registration Statement on Form S-1 (File No. 333-276315) for a proposed public offering of securities.

S-1 filing: The filing is an S-1 form indicating an offering of common stock with the underwriter having an option to purchase additional shares to cover over-allotments.

10-Q filing | 9.2M shares outstanding

8-K filing: Palisade Bio, Inc. closed a registered direct offering of 2,339,398 shares of common stock at a purchase price of $0.84 per share on September 11, 2023, resulting in gross proceeds of approximately $1.97 million. ($1.97M proceeds)

8-K filing: Palisade Bio, Inc. appointed Mitchell Jones as Chief Medical Officer and granted him inducement options to purchase 75,000 shares and 54,700 restricted stock units.

10-Q filing | 6.4M shares outstanding

8-K filing: Palisade Bio, Inc. approved supplemental grants of 245,660 common stock purchase options and 112,030 restricted stock units to employees, and grants of either 5,160 common stock purchase options or a combination of 2,580 common stock purchase options and 1,880 restricted stock units to each of the seven non-management members of the Board.

10-Q filing | 6.7M shares outstanding

S-1/A filing: This S-1/A filing relates to the resale of up to 3,925,492 shares of common stock by selling stockholders.

S-1 filing: This S-1 filing relates to the resale by selling stockholders of up to 3,925,492 shares of common stock.

8-K filing: Palisade Bio, Inc. closed a registered direct offering and concurrent private placement on April 5, 2023, resulting in gross proceeds of approximately $6.0 million.

10-K filing | 4.5M shares outstanding

8-K filing: On February 6, 2023, Palisade Bio, Inc. issued common stock purchase options, restricted stock units and performance restricted stock units to certain officers and members of senior management of the Company as conditional grants, subject to shareholder approval. On February 8, 2023, the Company issued a press release announcing the appointment of Mr. McRae as Chief Operating Officer and the appointment of Mr. Finley to the Board.

S-1 filing: Resale of up to 1,654,578 shares of common stock by selling stockholders upon exercise of prefunded warrants, common stock purchase warrants and placement agent warrants.

8-K filing: Palisade Bio, Inc. completed a registered direct offering of 476,842 shares of common stock at $2.375 per share and prefunded warrants to purchase up to 37,000 shares at $2.3749 per warrant, along with concurrent private placements of prefunded warrants and common stock purchase warrants, resulting in gross proceeds of approximately $2.5 million.

8-K filing: Stock split 1-for-50 | Outstanding: 77,080,169 → 1,541,603

10-Q filing | 77.1M shares outstanding

8-K filing: Palisade Bio, Inc. completed a public offering on August 16, 2022, issuing 49,360,000 shares of common stock, 1,460 shares of Series B Preferred Stock, 55,200,000 Series 1 Warrants, and 55,200,000 Series 2 Warrants, resulting in net proceeds of approximately $12.2 million. ($0.0M proceeds)

10-Q filing | 20.3M shares outstanding

S-1/A filing: This is an S-1/A filing that includes information regarding recent sales of unregistered securities, including issuances of Series P and Series Q warrants, warrants issued to Wainwright, and a private placement transaction with Altium Growth Fund, LP.

S-1/A filing: This S-1/A filing outlines an offering of Class A Units (each consisting of one share of common stock and warrants) and Class B Units (each consisting of one share of Series B Preferred Stock convertible into common stock and warrants).

S-1/A filing: The filing discusses recent sales of unregistered securities since January 1, 2019, including issuances of warrants and common stock in connection with various agreements and private placements.

S-1/A filing: This S-1/A filing relates to an offering of Class A Units, each consisting of one share of common stock and a warrant, and Class B Units, each consisting of one share of Series B Preferred Stock and a warrant, along with Representative Warrants.

S-1/A filing: This S-1/A filing registers 3,865,491 shares of common stock for resale by selling securityholders, issuable upon the exercise of warrants, with the company not receiving any proceeds from the sale but potentially receiving $2.7 million upon cash exercise of the warrants.

S-1 filing: S-1 filing on 2022-06-14 for the resale of up to 3,865,491 shares of common stock issuable upon the exercise of warrants by selling securityholders.

10-Q filing | 21.9M shares outstanding

S-3/A filing: This is an S-3/A filing for a delayed or continuous shelf offering of common stock by Palisade Bio, Inc.

8-K filing: Palisade Bio, Inc. reports that as of April 19, 2022, it had 18,233,479 shares of common stock outstanding, and the May 2021 Warrants were fully exercised into shares of the company's common stock through cashless exercises on February 2, 2022, and March 15, 2022.

S-3 filing: The filing relates to the offer and resale of up to 2,250,000 shares of common stock issuable upon the exercise of a warrant by the selling stockholder.

S-3 filing: The company may offer and sell up to an aggregate amount of $100,000,000 of any combination of common stock, preferred stock and/or debt securities.

10-K filing | 18.2M shares outstanding

8-K filing: Palisade Bio, Inc. issued a warrant to Altium Growth Fund, LP to purchase up to 2,250,000 shares of the Company's common stock with an exercise price of $1.10 as consideration for waiving certain anti-dilution protections.

S-3/A filing: This S-3/A filing registers 1,887,370 shares of common stock for resale by a selling stockholder, including shares and shares issuable upon exercise of a warrant, with the company receiving no proceeds from the sale.

10-Q filing | 13.6M shares outstanding

S-3 filing: The filing registers 1,887,370 shares of common stock for resale by a selling stockholder, including shares and shares issuable upon warrant exercise, with the company receiving no proceeds and paying for registration expenses.

8-K filing: Palisade Bio, Inc. entered into a Securities Purchase Agreement with Yuma Regional Medical Center, pursuant to which the Investor purchased 1,509,896 shares of the Company's common stock and a warrant to purchase up to 377,474 shares of Common Stock for a total purchase price of $5,209,141.20. ($5.21M proceeds)

10-Q filing | 11.4M shares outstanding

S-3 filing: This S-3 filing covers the offer and resale of up to 7,262,460 shares of common stock issuable upon the exercise of warrants by the selling stockholder.

8-K filing: Palisade Bio, Inc. issued a warrant to Altium Growth Fund, LP to purchase up to 1,100,000 shares of common stock with an exercise price of $3.631 as consideration for waiving certain rights and restrictions related to previous warrants.

8-K filing: On June 11, 2021, a reset occurred, disbursing the final 307,675 Additional Shares from escrow to the Investor and adjusting the Equity Warrant to become exercisable for 5,303,568 shares of Common Stock at an exercise price of $3.88 per share.

8-K filing: Palisade Bio, Inc. issued shares and warrants to Ecoban Securities, LLC, and warrants to Altium Growth Fund, LP and Noteholders in connection with the closing of a merger and pre-merger financing.

10-Q filing | 7.3M shares outstanding

10-K filing | 17.3M shares outstanding

10-Q filing | 17.3M shares outstanding

S-3 filing: Seneca Biopharma, Inc. intends to offer up to $100,000,000 of common stock, preferred stock and purchase contracts.

10-Q filing | 17.3M shares outstanding

8-K filing: Seneca Biopharma, Inc. sold 5,000,000 shares of common stock at $1.00 per share to institutional investors, resulting in gross proceeds of $5.0 million, which closed on May 27, 2020. ($5.0M proceeds)

10-Q filing | 9.4M shares outstanding

S-3/A filing: Selling stockholders are offering up to 5,999,998 shares of common stock underlying warrants.

10-K filing | 9.4M shares outstanding

S-3 filing: Selling stockholders are offering up to 5,999,998 shares of common stock.

8-K filing: Seneca Biopharma, Inc. entered into a letter agreement with certain institutional holders to reduce the exercise price of Series M and Series N Warrants from $2.70 to $1.36 per share, with the holders exercising all 2,777,777 Series M Warrants and 2,777,777 Series N Warrants, and the company anticipating gross proceeds of approximately $7,555,553. ($7.56M proceeds)